AstraZeneca Signs USD 1.77 Billion Pact with CSPC to Develop Kidney Disease Therapies
Shanghai: AstraZeneca has entered into a deal worth up to USD 1.77 billion with CSPC Pharmaceutical Group to discover and develop experimental medicines with the potential to treat kidney diseases, the Chinese drugmaker said on Thursday.
CSPC's Hong Kong stock exchange filing did not disclose the specific diseases the medicines would target. The World Health Organization says an estimated 674 million people worldwide have chronic kidney disease, which progresses gradually.
AstraZeneca will have the option to obtain exclusive rights to develop, manufacture and commercialise one preclinical small nucleic acid drug candidate globally, and a second outside China.
CSPC is eligible to receive $30 million as an upfront payment and up to about $1.74 billion in additional payments tied to development and sales-related milestones
AstraZeneca has previously entered into collaborations with CSPC, including on obesity and weight-related conditions
AstraZeneca declined to comment on what diseases would be targeted under the new CSPC deal
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.